Anagram Therapeutics

Anagram Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oral enzyme therapies for the treatment of severe diseases caused by malabsorption syndromes and nutritional metabolic disorders, which prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins, or other key nutrients. The company is leveraging proprietary enzyme technology and expertise in gastrointestinal diseases to address complex issues and advance a pipeline of products that can bring life-changing impacts to individuals with cystic fibrosis and other rare diseases, as well as their families. ANG003, Anagram’s lead product for treating malabsorption and exocrine pancreatic insufficiency, is a novel broad-spectrum digestive enzyme replacement therapy currently in clinical trials for patients with cystic fibrosis.